Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
CORTES, JORGE E
One or more keywords matched the following items that are connected to CORTES, JORGE E
Item TypeName
Concept Drug Monitoring
Academic Article Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Academic Article Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Academic Article Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Academic Article Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.
Academic Article Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Academic Article Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Academic Article Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Academic Article Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Academic Article Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Academic Article Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Academic Article On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Academic Article Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Search Criteria
  • Drug Monitoring